20 recruiting, 6 completed, 6 terminated, 4 unknown. 29 Phase 1, 14 Phase 2, 3 Early Phase 1, 1 Phase 3.
Follow Acute Myeloid Leukemia, in Relapse: new trials by email Literature Review of Acute Myeloid Leukemia, in Relapse trials Research Report on Acute Myeloid Leukemia, in Relapse
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Long-term Follow-up Study of Patients With ARD103 CAR-T Cell Therapies Non interventional study - Acute Myeloid Leukemia, in Relapse, Acute Myeloid Leukemia, in Relapsed or Refractory | Not yet recruiting | ARCE Therapeutics, Inc. | 49 | 2026-03-15 | 2025-12-08 | |
| Adoptive T Cell Therapy With DC/AML Fusion Vaccine Plus Decitabine and Venetoclax in AML DC/AML Fusion Vaccine, T-Cell Therapy, Decitabine - Acute Myeloid Leukemia, Acute Myeloid Leukemia, in Relapse | Phase 1 | Recruiting | David Avigan | 30 | 2026-02-12 | 2026-05-05 |
| Radioimmunotherapy Conditioning With 131I- Apamistamab for Allogeneic Transplant in Relapse/Refractory AML 131I-apamistamab, Fludarabine, Cyclophosphamide - Acute Leukemia, Myeloid Leukemia | Phase 2 / Phase 3 | Not yet recruiting | Actinium Pharmaceuticals | 306 | 2026-01-01 | 2025-09-10 |
| An Adaptive Open-label Multicentre Phase 1/2 Trial, to Determine the Recommended Phase 2 Dose of CCTx-001, and to Assess Safety, Tolerability, and Clinical Activity in Patients With Relapsed/Refractory Acute Myeloid Leukaemia CCTx-001 - Acute Myeloid Leukemia, in Relapse, Acute Myeloid Leukemia Refractory | Phase 1 / Phase 2 | Not yet recruiting | Advesya SAS | 143 | 2025-12-01 | 2025-09-18 |
| Study of C6 Ceramide NanoLiposome (CNL) in Patients With Relapsed/Refractory Acute Myeloid Leukemia Ceramide NanoLiposome (Ceraxa) - Acute Myeloid Leukemia, in Relapse, Acute Myeloid Leukemia, Refractory | Phase 1 | Recruiting | Keystone Nano, Inc | 15 | 2025-10-01 | 2026-03-31 |
| Safety of MT-401-OTS in Patients With Relapsed AML or MDS MT-401-OTS - Acute Myeloid Leukemia, in Relapse, MDS | Phase 1 | Recruiting | Marker Therapeutics, Inc. | 40 | 2025-06-16 | 2025-12-16 |
| A Study of Natural Killer Cells in Combination With Atezolizumab in People With Acute Myelogenous Leukemia Cytokine Induced Memory-Like Natural Killer Cells, Atezolizumb, CIML-NK cell therapy - Acute Myeloid Leukemia Refractory, Acute Myeloid Leukemia, in Relapse | Phase 1 | Recruiting | Memorial Sloan Kettering Cancer Center | 18 | 2025-05-30 | 2026-06-17 |
| Clinical Study of ARD103 CAR-T Therapy for Patients With R/R AML or MDS ARD103, Cyclophosphamide, Fludarabine - Acute Myeloid Leukemia, in Relapse, Acute Myeloid Leukemia Refractory | Phase 1 / Phase 2 | Recruiting | ARCE Therapeutics, Inc. | 49 | 2025-05-20 | 2025-12-10 |
| CPI-613 Given With Metformin in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) CPI 613, Metformin, Blood draws - Acute Myeloid Leukemia, in Relapse, Acute Myeloid Leukemia Refractory | Phase 2 | Withdrawn | Wake Forest University Health Sciences | 2024-12-01 | 2024-09-19 | |
| Master Framework For Relapse or Refractory Acute Myeloid Leukemia Registration into the STREAM platform - Acute Myeloid Leukemia, in Relapse, Acute Myeloid Leukemia Refractory | Recruiting | Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS | 4000 | 2024-06-28 | 2026-08-14 | |
| A Study to Investigate APL-4098 Alone and in Combination in Adults With AML or MDS APL-4098, Azacitidine and APL-4098, Azacitidine and Venetoclax and APL-4098 - Acute Myeloid Leukemia Refractory, Myelodysplastic Syndrome Acute Myeloid Leukemia | Phase 1 | Recruiting | Apollo Therapeutics Ltd | 100 | 2024-06-04 | 2026-06-01 |
| Sorafenib Relapase Prophylaxis After HCT With PTBCy Regimen Sorafenib - Acute Myeloid Leukemia, in Relapse, Myelodysplastic Syndromes | Phase 2 | Recruiting | St. Petersburg State Pavlov Medical University | 88 | 2024-05-22 | 2024-08-01 |
| CRISPR-Edited Allogeneic Anti-CLL-1 CAR-T Cell Therapy in Patients With Relapsed/Refractory Acute Myeloid Leukemia CB-012 - Acute Myeloid Leukemia, in Relapse, Acute Myeloid Leukemia Refractory | Phase 1 | Terminated | Caribou Biosciences, Inc. | 12 | 2024-02-08 | 2025-06-11 |
| Phase 1 Study of Allo-RevCAR01-T-CD123 in Patients With Selected CD123 Positive Hematologic Malignancies (1b Dose Expansion) Cyclophosphamide (Non-IMP, Lymphodepletion), Fludarabine (Non-IMP, Lymphodepletion), R-TM123 - Acute Myeloid Leukemia, in Relapse, Acute Myeloid Leukemia Refractory | Phase 1 | Recruiting | AvenCell Europe GmbH | 37 | 2024-01-03 | 2026-09-24 |
| Off-the-shelf CD123 CAR-NK for R/R AML JD123 injection - Acute Myeloid Leukemia, in Relapse, Acute Myeloid Leukemia Refractory | Early Phase 1 | Recruiting | Peking University People's Hospital | 12 | 2023-12-30 | 2025-03-11 |
| Administration of Anti Tim-3/CD123 CAR-T Cell Therapy in Relapsed and Refractory Acute Myeloid Leukemia (rr/AML) anti Tim-3/CD123 CAR-T cell therapy - Acute Myeloid Leukemia Refractory, Acute Myeloid Leukemia, in Relapse | Phase 1 / Phase 2 | Recruiting | Xuzhou Medical University | 20 | 2023-11-04 | 2023-11-09 |
| A Study of CD371-YSNVZIL-18 CAR T Cells in People With Acute Myeloid Leukemia CD371-specific/YSNVz/I-18 CAR T cells - Refractory Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia | Phase 1 | Recruiting | Memorial Sloan Kettering Cancer Center | 15 | 2023-09-01 | 2026-10-06 |
| A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML Ziftomenib, Venetoclax, Azacitidine - Acute Myeloid Leukemia, Mixed Lineage Leukemia Gene Mutation | Phase 1 | Recruiting | Kura Oncology, Inc. | 420 | 2023-07-18 | 2026-03-13 |
| Venetoclax to Augment Epigenetic Modification and Chemotherapy Venetoclax, Azacitadine, Vorinostat - Acute Myeloid Leukemia, in Relapse, Acute Myeloid Leukemia Refractory | Phase 1 | Recruiting | Medical College of Wisconsin | 40 | 2023-03-31 | 2026-01-12 |
| Evaluation of the Safety and Efficacy of Esperanza Extract (PA001) Petiveria Alliacea Preparation, Placebo - Neoplasm, Stomach, Gastric Neoplasms Malignant | Phase 1 / Phase 2 | Unknown | Hospital Universitario San Ignacio | 82 | 2022-12-15 | 2022-10-19 |
Showing 20 of 42. Sign in to see all of them.
Leukemia, Myeloid, Acute (42) · Recurrence (6) · Leukemia (4) · Anemia, Refractory, with Excess of Blasts (3) · Myelodysplastic Syndromes (3) · GATA2 Deficiency (2) · Leukemia, Biphenotypic, Acute (2) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (2) · Sarcoma, Myeloid (2) · Colorectal Neoplasms (1) · Graft vs Host Disease (1) · Hematologic Neoplasms (1) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (1) · Leukemia, Myeloid (1) · Myeloproliferative Disorders (1)
Hematologic Diseases (42) · Hemic and Lymphatic Diseases (42) · Neoplasms (42) · Neoplasms by Histologic Type (42) · Leukemia, Myeloid (41) · Leukemia (38) · Bone Marrow Diseases (7) · Disease Attributes (7) · Pathologic Processes (7) · Pathological Conditions, Signs and Symptoms (7) · Immune System Diseases (4) · Myelodysplastic Syndromes (4) · Anemia (3) · Anemia, Refractory (3) · Immunoproliferative Disorders (3)
fludarabine (8) · venetoclax (8) · Cyclophosphamide (6) · Cytarabine (3) · Decitabine (3) · Azacitidine (2) · Filgrastim (2) · Blood Specimen Collection (1) · DAV regimen (1) · Daunorubicin (1) · Granulocyte Colony-Stimulating Factor (1) · Granulocyte-Macrophage Colony-Stimulating Factor (1) · Immunotherapy, Adoptive (1) · KPT-9274 (1) · Mercaptopurine (1)
ARCE Therapeutics, Inc. (2) · Memorial Sloan Kettering Cancer Center (2) · University of Pennsylvania (2) · Xuzhou Medical University (2) · AB Science (1) · Actinium Pharmaceuticals (1) · Advesya SAS (1) · All India Institute of Medical Sciences (1) · Apollo Therapeutics Ltd (1) · AvenCell Europe GmbH (1) · Beth Israel Deaconess Medical Center (1) · Bio-Path Holdings, Inc. (1) · Caribou Biosciences, Inc. (1) · Ciceri Fabio (1) · Cleave Therapeutics, Inc. (1)
United States (23) · France (5) · Germany (5) · Italy (4) · Spain (4) · Australia (3) · China (3) · Belgium (2) · Colombia (1) · Greece (1) · Lithuania (1) · Netherlands (1) · Poland (1) · Romania (1) · Russia (1)
David Avigan, MD (2) · Adriano Venditti, Professor, MD (1) · Ai-Min Hui, MD, PhD (1) · Bayard Powell, MD (1) · Brian Shaffer, MD (1) · Christopher Prior, Ph.D. (1) · Daniel Pollyea, MD (1) · Daniel Vlock, MD (1) · Fabio Ciceri, MD (1) · Gail J Roboz, MD (1) · Giovanni Martinelli, MD, Prof (1) · Jacques Vargaftig, MD (1) · Joshua F Zeidner, MD (1) · Kailin Xu, M.D., Ph.D. (1) · Kailin Xu, MD.,PD. (1)
PMID 16564913, PMID 20371346, PMID 20959411, PMID 22589701, PMID 24497570, PMID 24641416, PMID 25621950, PMID 25631767, PMID 25805929, PMID 25983002, PMID 27347147, PMID 27916294, PMID 28161329, PMID 28412099, PMID 28415728, PMID 29506548, PMID 31409768, PMID 31432232, PMID 31739095, PMID 31819192, PMID 32711004, PMID 32822582, PMID 33184339, PMID 33462499, PMID 35451199, PMID 35582564, PMID 37226312, PMID 37563608, PMID 39333315, PMID 40864984, PMID 42227701
2014 (1), 2019 (1), P30CA012197 (1), R44CA275609 (1)